Co-administration of BHQ880, a neutralizing antibody against Dkk1, with anti-MM and anti-resorptive therapy, resulted in only modest improvements in bone health in a cohort of MM patients with relapsed/refractory disease [35]. Here, DKK1 is linked to Miyoshi myopathy.